The current average analyst rating on the shares is "buy", with 3 strong buy or buy ratings, no hold ratings, and no sell or strong sell ratings.
The average consensus recommendation for the biotechnology and medical research peer group is "buy".
Wall Street's median 12-month price target for Gyre Therapeutics, Inc. is $18.00, about 181.2% above its Aug. 6 closing price of $6.40.
Gyre affirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million.
Other result drivers included a $3 million decrease in collaboration revenue after the Astellas agreement ended in March 2026.
Gyre Therapeutics said second-quarter revenue fell year over year but came in above analyst expectations, helped by higher ETUARY sales volumes driven by focused marketing efforts, according to the company.
The US-China biopharma firm reported Q2 revenue of , compared with the consensus estimate of from three analysts.
The company said its Q2 GAAP net loss widened, driven by higher research and development expenses and Cullgen acquisition costs.
It also reported a Q2 net loss of $14.27 million and a pretax loss of $14.43 million.
